Med Shop Total Care, Inc., Longview, TX

Is Med Shop Total Care, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Med Shop Total Care, Inc. hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file does list MED SHOP TOTAL CARE PHARMACY, LONGVIEW, a close but not exact match shown below.

Has Med Shop Total Care, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Mar 18, 2022), 1 warning letter close-out (Oct 11, 2023), 1 state referral letter (Oct 11, 2023) and 1 FMD-145 letter (Oct 11, 2023) for Med Shop Total Care, Inc. Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Med Shop Total Care, Inc.
Location
Longview, TX
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
1
Latest action on that page
Oct 11, 2023
FDA Data Dashboard inspections
3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
2 Form 483s, 11 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Med Shop Total Care, Inc., a 503A facility, with 6 dated actions.

Document
Oct 11, 2023State referral letterState Referral Letter Issued 10/11/2023Not linked by FDA
Oct 11, 2023FMD-145 letterFMD-145 Issued 10/11/2023fda.gov
Oct 11, 2023Warning letter close-outWarning Letter Closeout Issued 10/11/2023fda.gov
Jun 8, 2023Form 483483 Issued 06/08/2023FDA copy (archived)
Mar 18, 2022Warning letterWarning Letter (03/18/2022)FDA copy (archived)
Jul 27, 2021Form 483483 Issued 07/27/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Med Shop Total Care Inc., Longview, TX (FEI number 3002835459), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 8, 2023Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30028354591208023
Jul 27, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30028354591149755
Nov 1, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30028354591071015

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 11 numbered observations in all, across 2 inspections ending Nov 1, 2018 to Jun 8, 2023. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 16, 2023 to Jun 8, 2023: 1 observation

Firm on the cover
Med Shop Total Care Inc., 470 E Loop 281, Longview, TX 75605-7939
FEI number
3002835459
Establishment type on the cover
Produce of Sterile and Non Sterile Drugs
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Lack of routine environmental monitoring in the classified areas.

Specifically, your firm does not perform routine environmental monitoring, of the laptop, located adjacent to the Laminar Flow Hood (ISO5), 40Ct <Redacted B4> used to enter data into the logged formula worksheet during sterile human drug production. The surface of the laptop is frequently touched in-between filling sterile human drug products.

For example,

1 )During the production of Hydromorphone HCl PF 4MG/ML Injectable 21 ml, Lot 05162023@ <Redacted B4>, BUD 6/13/2023, I observed the sterile compounding technician touching the keyboard of the laptop to enter data between filling sterile syringes of finished drug product. Your firm does not perform environmental monitoring on the frequently touched surfaces of the laptop. The finished sterile drug product was released by your firm's pharmacist and distributed to the patient.

2) During the production of Morphine Sulfate-Baclofen PF 10/MG/100MCG, Lot 05162023@ <Redacted B4>, BUD 6/14/2023, I observed the sterile compounding technician touching the keyboard of the laptop to enter data between filling sterile syringes of finished drug product. ...

Read the full 483 (PDF on fda.gov)

Inspection Oct 15, 2018 to Nov 1, 2018: 10 observations

Firm on the cover
Med Shop Total Care Inc., 470 E Loop 281 C ITY, STATE.ZIP CODE, COUNTRY Longvie w, TX 75605 -7939
FEI number
3002835459
Establishment type on the cover
Producer of Sterile and Non -sterile Drugs
FDA district office on the cover
Not read
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

a) You had several environmental monitoring results where you did not identify the microorganism and continued to produce and clistribute sterile drug products without a comp]ete investigation and corrective actiom taken.

Human

Class

<Redacted B4> S07

2 cfu (fungal)

<Redacted B4> S07 1 cfu (fungi)

<Redacted B4> S07 5 cfu (counted)

<Redacted B4> S07 TNTC

<Redacted B4> S07

1 cfu q( <Redacted B4>

Veterinary

<Redacted B4> ISO 5 1 cfu

<Redacted B4> S07

TNTC

b) Employees had positive results multiple times for fingertip testing after producing sterile drug products. You did not identify the microorganism and continued to produce and distribute sterile drug products without a complete investigation and corrective action taken.

!Human Fingertip

<Re dacted B4> 3 cfu (L)

7 cfu (Rt)

3 cfu (L & Rt)

1 cfu (L) asperg

Veterinary Fingertip

<Redacted B4> 9 cfu (Rt)

12 cfu (L)

7 cfu (Rt)

c) Your written procedure does not address how microorganisms can affect the sterile drug product nor does it define the specific location of the sampling points. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Each batch of drug product required to be free ofobjectionable microorganisms is not tested through appropriate laboratory testing.

Specifically, you do not conduct sterility testing on any finished sterile drug products.

Observation 3

Each batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically,

a) You do not have endotoxin analysis for any of the sterile stock solutions of veterinary drug products you produce.

b) The endotoxin test method used for human sterile stock solution is not a compendia! method.

c) You do not conduct any endotoxin testing for any finished sterile drug products including intrathecal products that contain Morphine Sulfate, Bupivacaine, Fentanyl, Clonidine, Baclofen or Hydromorphone.

Observation 4

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically, you do not conduct any potency testing for finished sterile drug products.

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Specifically,

a) Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations. You do not include the smallest or largest batch size and different container types (vials).

b) Smoke studies have not been performed tmder dynamic conditions in ISO 5 areas. The smoke study you performed during the inspection onJ y included the hoods and biosafety cabinets only demonstrated pulling drug product from a vial into a syringe.

c) <Redacted B4> testing performed on finished products is not <Redacted B4> . In addition, the results of <Redacted B4> testing for veterinary products is not documented.

Observation 6

Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition.

Specifically,

a) I observed a brownish residue on top of the return air vent in the human clean room (ISO 7) where the laminar flow hoods and biosafety cabinet are located, and aseptic operations occur.

b) The seam on the floors for all rooms in the classified area is raised and not smooth.

c) All the <Redacted B4> are scratched and cloudy in appearance.

Observation 7

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, you do not have any hold time studies to support storing preservative free stock soJutions held in glass and pJastic vials and assigning beyond-use-dates of more than three months.

Observation 8

Clothing of personnel engaged in the manufacturing, processing, packing and holding of chug products is not appropiate for the duties they perform.

Specifically, the gown and mask worn by personnel on the veterinary side during sterile compounding is not sterile.

Observation 9

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

SpecificalJy, your formulation worksheets do not include specific instmctions. For example you do not have specifications/parameters putting the Morphine Sulfate Stock <Redacted B4> (time and temperature).

Observation 10

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically,

a) You do not use a hood to prepare non-sterile hormonal products. The capsule equipment is only cleaned with <Redacted B4> after use. You have no further documentation to show prevention of contamination from one lot to another lot.

b) You also only use non-sterile~ <Redacted B4> to clean the cabinet area where non-sterile operations occur.

Linked 483s whose text is not shown

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

Close but not exact board records

These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.